ST-920
ST-920-LT01
Phase 2 small_molecule active
Quick answer
ST-920 for Fabry Disease (X-linked lysosomal storage disease). is a Phase 2 program (small_molecule) at SANGAMO THERAPEUTICS, INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- SANGAMO THERAPEUTICS, INC
- Indication
- Fabry Disease (X-linked lysosomal storage disease).
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active